PMID- 22300682
OWN - NLM
STAT- MEDLINE
DCOM- 20120723
LR  - 20151119
IS  - 1873-5487 (Electronic)
IS  - 0188-4409 (Linking)
VI  - 43
IP  - 1
DP  - 2012 Jan
TI  - Serum chemokines RANTES and monocyte chemoattractant protein-1 in Egyptian 
      patients with atopic asthma: relationship to disease severity.
PG  - 36-41
LID - 10.1016/j.arcmed.2012.01.009 [doi]
AB  - BACKGROUND AND AIMS: Asthma is a highly prevalent, complex inflammatory disease 
      of the airways often associated with bronchial hyperreactivity and atopy. The 
      chemokine RANTES (regulated upon activation, normal T -cell expressed and 
      secreted) is an important element for the chemotaxis at the site of allergic 
      inflammation. This study aimed to assess the serum levels of the chemokines 
      RANTES and monocyte chemoattractant protein-1 (MCP-1) in Egyptian patients with 
      atopic asthma and to evaluate their possible relation t the severity of airway 
      obstruction. METHODS: The study included 60 Egyptian patients with atopic asthma 
      and 20 healthy volunteers. Serum levels of the chemokines RANTES and MCP-1 were 
      measured. Total serum IgE level and absolute eosinophil counts were determined. 
      The severity of airway obstruction was assessed using spirometric measurement 
      (FEV(1)). RESULTS: The serum levels of RANTES were significantly higher in all 
      asthmatic patients than the controls (p <0.001). Moreover, RANTES levels were 
      significantly increased in patients with moderate and severe asthma as compared 
      to those with mild asthma (p <0.001). Serum RANTES correlated positively with 
      absolute eosinophil counts and total serum IgE and negatively with FEV(1), 
      whereas there was no significant correlation with serum MCP-1 in all asthmatic 
      patients. CONCLUSIONS: Serum RANTES may be used as a useful noninvasive marker of 
      airway obstruction and a potential diagnostic tool for monitoring asthma 
      severity. In this regard, identification and blocking of this chemokine and/or 
      its receptor may be a promising therapeutic approach to asthmatic patients.
CI  - Copyright (c) 2012 IMSS. All rights reserved.
FAU - Saad-El-Din Bessa, Sahar
AU  - Saad-El-Din Bessa S
AD  - Department of Internal Medicine, Faculty of Medicine, Tanta University, Egypt. 
      saharbessa@yahoo.com
FAU - Abo El-Magd, Gehan Hassan
AU  - Abo El-Magd GH
FAU - Mabrouk, Maaly Mohamed
AU  - Mabrouk MM
LA  - eng
PT  - Journal Article
DEP - 20120131
PL  - United States
TA  - Arch Med Res
JT  - Archives of medical research
JID - 9312706
RN  - 0 (Biomarkers)
RN  - 0 (CCL5 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adult
MH  - Asthma/*blood/pathology
MH  - Biomarkers/blood
MH  - Blood Cell Count
MH  - Case-Control Studies
MH  - Chemokine CCL2/*blood
MH  - Chemokine CCL5/*blood
MH  - Egypt
MH  - Female
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Male
MH  - Middle Aged
EDAT- 2012/02/04 06:00
MHDA- 2012/07/24 06:00
CRDT- 2012/02/04 06:00
PHST- 2011/11/12 00:00 [received]
PHST- 2012/01/18 00:00 [accepted]
PHST- 2012/02/04 06:00 [entrez]
PHST- 2012/02/04 06:00 [pubmed]
PHST- 2012/07/24 06:00 [medline]
AID - S0188-4409(12)00036-7 [pii]
AID - 10.1016/j.arcmed.2012.01.009 [doi]
PST - ppublish
SO  - Arch Med Res. 2012 Jan;43(1):36-41. doi: 10.1016/j.arcmed.2012.01.009. Epub 2012 
      Jan 31.